Related Experiment Video

Updated: May 28, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Axitinib in the treatment of metastatic renal cell carcinoma

Thai H Ho1, Eric Jonasch

  • 1Department of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.

Future Oncology (London, England)
|November 3, 2011
PubMed

Insights

Axitinib, a targeted therapy for angiogenesis, shows promise in advanced renal cell carcinoma. Ongoing trials are evaluating its use as a first-line treatment option.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced renal cell carcinoma (RCC) is a significant clinical challenge.
  • Angiogenesis plays a critical role in RCC progression.
  • Targeted therapies offer new treatment avenues for advanced RCC.

Purpose of the Study:

  • To evaluate the efficacy and safety of axitinib in advanced renal cell carcinoma.
  • To explore the potential of axitinib as a second-line and first-line treatment for advanced RCC.

Main Methods:

  • Axitinib, an oral small-molecule tyrosine kinase inhibitor, was investigated.
  • Clinical trials were conducted to assess its activity in advanced RCC patients.

Main Results:

  • Axitinib demonstrated activity in advanced renal cell carcinoma.
  • Common side effects observed include hypertension, fatigue, and dysphonia.

Conclusions:

  • Axitinib is a promising targeted therapy for advanced renal cell carcinoma.
  • Further trials are ongoing to establish its role in both second-line and first-line settings.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...